Delivery Order SPE2DB25D3018-SPE2DB26FUWTQ
- Not listed
- The Defense Logistics Agency awarded a $36,747.91 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampuls (2.5 ml units) with an ultimate completion date of October 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,669.46 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. This child delivery order, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, was competitively awarded with firm fixed price terms and no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $2,599.62 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml) on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a single delivery order against AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL, a pharmaceutical product used in treating cystic fibrosis. This firm fixed-price delivery order, valued at $48,360.96, was competitively awarded without set-aside designation and carries an ultimate completion date of October 22, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product commonly used in cystic fibrosis treatment. This non-set-aside, firm fixed-price delivery order has a ceiling value of $16,287.62 and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $5,167.20 delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampules (2.5 ml units) under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a purchase order for a respiratory medication commonly used in the treatment of cystic fibrosis and is being delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. The contract was awarded on...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,356.71 to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampule 2.5ml pharmaceutical supplies. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 18, 2025, issued on September 17, 2025. The contract will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $11.9K delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/mL ampul 2.5mL pharmaceutical product, with an ultimate completion date of July 28, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. This firm fixed price contract, valued at $5,167.20, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,533.25 to AmerisourceBergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. The contract was competitively awarded on August 12, 2025, under a firm fixed-price arrangement with an ultimate completion date of August 13, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB26FUWTQDelivery Order
The Defense Logistics Agency awarded a $2,583.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pulmozyme 1 mg/ml ampul 2.5ml, a pharmaceutical product used in the treatment of cystic fibrosis. The contract, awarded on October 24, 2025, with an ultimate completion date of October 27, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through DLA's Medical Supply Chain. The company holds a $999,999,999 prime indefinite delivery contract (SPE2DX) with DLA Troop Support Medical through December 2026, which enables the delivery of a comprehensive range of pharmaceutical products, medical supplies, and specialty medications to support global military healthcare programs. This specific delivery order for Pulmozyme exemplifies the company's role in fulfilling federal medical supply requirements across multiple therapeutic domains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 10/24/25 |